Safe/more effective therapies for metabolic diseases. Imeglimin (mitochondria-based MOA) for T2D began Ph 3 in Japan with Asian partner Sumitomo Dainippon. Completion of Phase 3 on track for 2019 and JNDA submission in 2020. In 1Q18, announced agreement w Roivant for Imeglimin (Ph 3 ready) in US, EU, and addl countries WW. PXL770: direct AMPK activator entering Phase 2a for NASH in Q418. PXL065 (deuterium-stabilized R-pioglitazone), mitochondrial pyruvate carrier (MPC), in Ph 1 for treatment of NASH.
261 avenue Jean Jaurès
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by